The Oncology Institute, Inc.
NASDAQ:TOIMedical - Care Facilities
-$0.07 today
- Market cap
- $512.91M
- Beta
- 0.41
- P/E (TTM)
- -121.1
- EPS (TTM)
- -$0.04
Volume 1.21M
Average 1.74M
TOI Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
The Oncology Institute, Inc.NASDAQ: TOI
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $125.74M rose 44.3% year over year, ahead of the +35.2% change in trailing-twelve-month cost of revenue. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at +28.6% a year.
Context
- Cost of revenue amounted to 84.8% of revenue in FY2025, down 1.5 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +44.3% holds above the trailing-twelve-month pace of +35.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 426.29M USD
- Year-over-year change
- +25.6%
- 4-year CAGR
- +27.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 426.29M | +25.6% |
| FY2024 | 2024-12-31 | 339.42M | +28.2% |
| FY2023 | 2023-12-31 | 264.67M | +32.1% |
| FY2022 | 2022-12-31 | 200.39M | +23.6% |
| FY2021 | 2021-12-31 | 162.16M | — |
Cost of Revenue vs competitors
How TOI compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +35.2% is the 2nd highest of 10, against a peer median of +5.6%.
- Cost of revenue amounts to 85.2% of revenue for TOI, versus a peer median of 62.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.98B USD | -0.5% | +39.0% | 102.7% | |
AUNAAuna S.A. | LTM Mar 2026 | PEN 2.81B PEN | +5.6% | +20.1% | 62.1% |
| LTM Mar 2026 | $803.11M USD | -19.9% | -26.7% | 80.2% | |
| LTM Mar 2026 | $534.91M USD | +7028.0% | +146.8% | 129.9% | |
| LTM Mar 2026 | $464.88M USD | +35.2% | +28.6% | 85.2% | |
| LTM Mar 2026 | $103.98M USD | +17.4% | +21.1% | 34.5% | |
| LTM Mar 2026 | $102.95M USD | -34.6% | — | 111.2% | |
| LTM Mar 2026 | $65.51M USD | +13.4% | +26.3% | 26.9% | |
| LTM Mar 2026 | $42.05M USD | +1.0% | +16.0% | 20.3% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $11.68M USD | +28.7% | +34.5% | 12.3% |
| Peer median (excluding TOI) | — | +5.6% | +23.7% | 62.1% | |
Competitors are the stored peer set for TOI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 203M | 252.48M | 324.24M | 393.41M | 502.73M |
| Cost of Revenue | 162.16M | 200.39M | 264.67M | 339.42M | 426.29M |
| Gross Profit | 40.85M | 52.09M | 59.57M | 54M | 76.44M |
| Gross Margin | 20.1% | 20.6% | 18.4% | 13.7% | 15.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 105.57M |
| Operating Expenses | 86.71M | 134.04M | 136.59M | 114.12M | 112.52M |
| Depreciation & Amortization | 3.34M | 4.41M | 5.87M | 6.29M | 6.94M |
| EBITDA | (42.04M) | (67.6M) | (54.28M) | (50.88M) | (42.52M) |
| EBITDA Margin | -20.7% | -26.8% | -16.7% | -12.9% | -8.5% |
| Operating Income | (45.86M) | (81.95M) | (77.02M) | (60.12M) | (36.08M) |
| Operating Margin | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 320K | 4.08M | 6.78M | 7.5M | 11.28M |
| Other Income / Expenses | 34.26M | 81.86M | (6.09M) | (4.55M) | (24.65M) |
| Income Before Tax | (11.6M) | (91K) | (83.1M) | (64.66M) | (60.74M) |
| Pre-Tax Margin | -5.7% | -0.0% | -25.6% | -16.4% | -12.1% |
| Income Tax Expense | (671K) | (243K) | (36K) | 0 | (131K) |
| Net Income | (10.93M) | 152K | (83.07M) | (64.66M) | (60.61M) |
| Net Margin | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
| EPS (Basic) | (0.16) | 0.00 | (0.92) | (0.71) | (0.54) |
| EPS (Diluted) | (0.16) | (0.21) | (0.92) | (0.71) | (0.54) |
| Weighted Avg Shares | 66.23M | 72.79M | 73.75M | 75.04M | 923.89M |
| Weighted Avg Shares (Diluted) | 66.23M | 80.61M | 73.75M | 75.04M | 923.89M |
The Oncology Institute, Inc.
NASDAQ:TOI
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.